ClinicalTrials.gg
CompletedNCT00353873Updated May 29, 2018Results posted

Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids

A Phase 4 interventional study of Fluticasone propionate and Fluticasone propionate/salmeterol in Asthma, sponsored by GlaxoSmithKline. Completed at 65 sites in 12 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2018-05-29.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Nov 2005, registered Jul 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
506
Allocation
Randomized
Ages
4 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
28th of 146
506 · median 100
Started
2005
with 8 others
Phase 4
52 of 147
1 open now
Registered
18th of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 28th largest by enrollment of the 146 interventional ones that give a count, is one of 9 that started in 2005, is one of 52 in phase 4, and was the 18th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This study will compare two treatment strategies (doubling the dose of inhaled steroids or adding a long acting beta2 agonist to the inhaled steroid at the same dose) in children not controlled by inhaled steroid alone at medium dose. The fixed combination SERETIDE 100/50 one inhalation twice daily will be compared to FLIXOTIDE 100 two inhalations twice daily.

Read the detailed description

A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100mcg twice daily and fluticasone propionate (FLIXOTIDE™) at a dose of 200mcg twice daily, both delivered via a dry powder inhaler (DISKUS™) for 12 weeks in asthma in children aged 4-11 years not controlled by inhaled corticosteroids alone at medium dose

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • FLIXOTIDE
  • asthmatics children 4-11 years
  • SERETIDE
  • asthma-control
04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A documented clinical history of asthma for a period of at least 6 months.
  • A documented history (within 12 months of Visit 1) of airway reversibility of = 15% based either on (FEV1) or PEF measured pre and post inhalation of 200 mcg salbutamol. (If no documented history of reversibility exists, patients must demonstrate a =15% reversibility at Visit 1).
  • Receiving an inhaled at a medium dose (beclomethasone dipropionate HydroFluoroAlkane (HFA) non fine particle = 400-500 mcg/day or beclomethasone HFA fine particle = 200mcg/day, or budesonide =400 mcg/day or fluticasone = 200 mcg/day (or fluticasone 250mcg/day if subject is taking a 125mcg MDI rather than the 100mcg Diskus), for at least 3 months prior to Visit 1 and at a stable dose for at least 4 weeks prior to Visit 1.
  • Able to use the Mini-Wright peak flow meter and subject or parent/guardian had to be able to record the subject's maximum PEF correctly.
  • Able to perform FEV1 correctly.
  • Subject's guardian/parent able to complete an eDRC on behalf of the subject. The eDRC should be completed by the guardian/parent.
  • Able to use a DISKUS™ correctly.
  • At least one parent(s)/guardian(s) has to give written to participate in the study.

At the end of the run-in period (Visit 2), subjects must still meet the criteria for entry into the run-in period and also have:

  • not achieved the criteria for the 'Well-controlled' asthma during two or more of the 4 weeks prior to Visit 2.

Exclusion criteria

Exclusion criteria:

  • Female subjects who have reached menarche.
  • Received any study medication in the 4 weeks prior to Visit 1.
  • Experienced a respiratory tract infection in the 4 weeks prior to Visit 1.
  • Experienced an acute asthma exacerbation requiring emergency room treatment within 4 weeks or hospitalisation within 12 weeks of Visit 1.
  • Any use of oral/parenteral or depot within 12 weeks of Visit 1.
  • Any use of long-acting inhaled beta2-agonists or oral beta2-agonists within 4 weeks of Visit 1.
  • Any use of leukotriene antagonists or theophyllines within 4 weeks of Visit 1.
  • Any known clinical or laboratory evidence of a serious uncontrolled disease (including serious psychological disorders) which is, in the opinion of the investigator, likely to interfere with the study.
  • Subjects with a known or suspected to inhaled corticosteroids, beta2-agonists, or any components of the formulations (e.g. lactose)
  • A relative of any of the site staff, including the investigator or study co-coordinator.
  • Has previously been entered into this study.

Subjects will be excluded from participating in the treatment period of the study if the following occurred during the run-in period:

  • Pre-bronchodilator \<60% (assuming that measurement was correctly performed).
  • Any change in asthma medication (excluding use of prophylactic study specific salbutamol for prevention of asthma symptoms due to exercise).
  • Respiratory tract infection or asthma exacerbation.
  • Use of oral, parenteral or depot corticosteroids.
  • Emergency visit due to asthma.
  • Non-compliance with the completion of the eDRC (i.e. during the 4 week period between visits, non compliance is defined as less than 5 days of completed data within any one week for four weeks - subjects must complete at least 5 days a week for the entire run-in period).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
506 participants (actual)

Study arms

  • Active comparator
    Fluticasone propionate (FLIXOTIDE™)

    Fluticasone propionate (FLIXOTIDE™) at a dose of 200μg twice daily

    Drug: Fluticasone propionate

  • Experimental
    Fluticasone propionate/salmeterol (SERETIDE™)

    Salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100μg twice daily

    Drug: Fluticasone propionate/salmeterol

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Morning Peak Expiratory Flow (PEF) Over 12 Weeks in Intent-to-treat (ITT) Population

    PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in electronic diary record card (eDRC), performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using analysis of covariance (ANCOVA) adjusted for baseline PEF, country amalgamation, age, sex and treatment.

    Time frame: Baseline; Week 1 up to Week 12

  2. Mean Change From Baseline in Morning PEF Over 12 Weeks in Per Protocol (PP) Population

    PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in eDRC, performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using ANCOVA adjusted for baseline PEF, country amalgamation, age, sex and treatment.

    Time frame: Baseline; Week 1 up to Week 12

Secondary outcomes

  1. Number of Participants Who Achieved 'Totally Controlled' (TC) Asthma

    TC asthma is defined as no daily symptoms, no night-time wakening due to asthma, no exacerbations, no rescue salbutamol/albuterol use, no emergency visits, \>=80% predicted morning PEF, and no treatment related adverse events enforcing a change in asthma therapy over 7 consecutive days. Number of participants/group who achieved the status of at least TC during the last 8 weeks (wks) of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline pre-bronchodilator Forced Expiratory Volume in one second (FEV1). Asthma control was assessed each week for the last 8 wks of treatment period. Each week was classified as 'TC', 'Well Controlled' (WC), 'Not Controlled' or 'Unevaluable'. A participant was considered to have TC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were TC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.

    Time frame: Week 5 up to Week 12

  2. Number of Participants Who Achieved WC Asthma

    WC asthma is defined as two or more of symptom score \>1 only allowed on \<=2 days/week, rescue salbutamol/albuterol use on \<=2 days/week and up to a maximum of 4 times per week, \>=80% predicted morning PEF daily assessed for 7 consecutive days and all the following criteria: no night-time awakening due to asthma, no exacerbations, no emergency visits, no treatment related adverse events enforcing a change in any asthma therapy. Number of participants/group who achieved the status of at least WC during the last 8 wks of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline prebronchodilator FEV1. Each week was classified as 'WC', 'Not Controlled' or 'Unevaluable'. A participant was considered to have WC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were WC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.

    Time frame: Week 5 up to Week 12

07

Results

Posted Apr 24, 2017

Participant flow

The study was conducted at 46 sites in 12 countries: Belgium (4), Denmark (1), France (8), Italy (3), Latvia (3), Lithuania (3), the Netherlands (6), Norway (1), Poland (4), Russian Federation (9), Spain (3) and Sweden (1) from 18 November 2005 to 26 October 2006.

Participant flow — Overall Study
MilestoneFP 200 mcg BDSalmeterol/Fluticasone Propionate (SFC) 50/100 mcg BD
Started153150
Completed147147
Not completed63
Withdrew: Protocol violation12
Withdrew: Exacerbation10
Withdrew: Adverse event10
Withdrew: Physician decision20
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryMean Change From Baseline in Morning Peak Expiratory Flow (PEF) Over 12 Weeks in Intent-to-treat (ITT) Population

PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in electronic diary record card (eDRC), performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using analysis of covariance (ANCOVA) adjusted for baseline PEF, country amalgamation, age, sex and treatment.

Time frame:
Baseline; Week 1 up to Week 12
Reported as:
Least squares mean · Liters/Minute (L/min)
Mean Change From Baseline in Morning Peak Expiratory Flow (PEF) Over 12 Weeks in Intent-to-treat (ITT) Population
Liters/Minute (L/min)FP 200 mcg BDSFC 50/100 mcg BD
Mean Change From Baseline in Morning Peak Expiratory Flow (PEF) Over 12 Weeks in Intent-to-treat (ITT) Population19.3 ± 2.1226.9 ± 2.13
Statistical analysis
  • FP 200 mcg BD vs SFC 50/100 mcg BD · ANCOVA · p = 0.012 · Mean difference (net): 7.6 · 95% CI 1.7 to 13.5
PrimaryMean Change From Baseline in Morning PEF Over 12 Weeks in Per Protocol (PP) Population

PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in eDRC, performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using ANCOVA adjusted for baseline PEF, country amalgamation, age, sex and treatment.

Time frame:
Baseline; Week 1 up to Week 12
Reported as:
Least squares mean · L/min
Mean Change From Baseline in Morning PEF Over 12 Weeks in Per Protocol (PP) Population
L/minFP 200 mcg BDSFC 50/100 mcg BD
Mean Change From Baseline in Morning PEF Over 12 Weeks in Per Protocol (PP) Population18.4 ± 2.1427.7 ± 2.21
Statistical analysis
  • FP 200 mcg BD vs SFC 50/100 mcg BD · ANCOVA · p = 0.003 · Mean difference (net): 9.3 · 95% CI 3.2 to 15.3
SecondaryNumber of Participants Who Achieved 'Totally Controlled' (TC) Asthma

TC asthma is defined as no daily symptoms, no night-time wakening due to asthma, no exacerbations, no rescue salbutamol/albuterol use, no emergency visits, \>=80% predicted morning PEF, and no treatment related adverse events enforcing a change in asthma therapy over 7 consecutive days. Number of participants/group who achieved the status of at least TC during the last 8 weeks (wks) of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline pre-bronchodilator Forced Expiratory Volume in one second (FEV1). Asthma control was assessed each week for the last 8 wks of treatment period. Each week was classified as 'TC', 'Well Controlled' (WC), 'Not Controlled' or 'Unevaluable'. A participant was considered to have TC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were TC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.

Time frame:
Week 5 up to Week 12
Reported as:
Number · Participants
Number of Participants Who Achieved 'Totally Controlled' (TC) Asthma
ParticipantsFP 200 mcg BDSFC 50/100 mcg BD
Number of Participants Who Achieved 'Totally Controlled' (TC) Asthma2328
Statistical analysis
  • FP 200 mcg BD vs SFC 50/100 mcg BD · Regression, Logistic · p = 0.389 · Odds ratio (or): 1.31 · 95% CI 0.7 to 2.4
SecondaryNumber of Participants Who Achieved WC Asthma

WC asthma is defined as two or more of symptom score \>1 only allowed on \<=2 days/week, rescue salbutamol/albuterol use on \<=2 days/week and up to a maximum of 4 times per week, \>=80% predicted morning PEF daily assessed for 7 consecutive days and all the following criteria: no night-time awakening due to asthma, no exacerbations, no emergency visits, no treatment related adverse events enforcing a change in any asthma therapy. Number of participants/group who achieved the status of at least WC during the last 8 wks of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline prebronchodilator FEV1. Each week was classified as 'WC', 'Not Controlled' or 'Unevaluable'. A participant was considered to have WC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were WC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.

Time frame:
Week 5 up to Week 12
Reported as:
Number · Participants
Number of Participants Who Achieved WC Asthma
ParticipantsFP 200 mcg BDSFC 50/100 mcg BD
Number of Participants Who Achieved WC Asthma6165
Statistical analysis
  • FP 200 mcg BD vs SFC 50/100 mcg BD · Regression, Logistic · p = 0.535 · Odds ratio (or): 1.16 · 95% CI 0.7 to 1.9

Adverse events

Collected over Serious adverse events and non-serious adverse events were collected from the first day of treatment until the last day of treatment (up to 12 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FP 200 mcg BD—3/153 (2%)61/153 (39.9%)
SFC 50/100 mcg BD—3/150 (2%)55/150 (36.7%)
Most frequent serious events
Most frequent serious events
EventFP 200 mcg BDSFC 50/100 mcg BD
ConcussionInjury, poisoning and procedural complications0/1531/150
AsthmaRespiratory, thoracic and mediastinal disorders1/1531/150
LaryngotracheitisInfections and infestations0/1531/150
GastritisGastrointestinal disorders1/1530/150
Wound infectionInfections and infestations1/1530/150
Most frequent other events
Most frequent other events
EventFP 200 mcg BDSFC 50/100 mcg BD
HeadacheNervous system disorders23/15327/150
NasopharyngitisInfections and infestations19/15314/150
RhinitisInfections and infestations10/15312/150
CoughRespiratory, thoracic and mediastinal disorders10/1537/150
Rhinitis allergicRespiratory, thoracic and mediastinal disorders10/1536/150
Abdominal painGastrointestinal disorders6/1538/150

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FP 200 mcg BDSFC 50/100 mcg BDTotal
Mean8.0 ± 2.018.1 ± 2.008.0 ± 2.00
Sex: Female, Male
Sex: Female, Male(Participants)FP 200 mcg BDSFC 50/100 mcg BDTotal
Female5553108
Male9897195
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FP 200 mcg BDSFC 50/100 mcg BDTotal
African American/African Heritage325
White - Arabic/North African Heritage448
White - White/Caucasian/European Heritage146144290
08

Study locations

65 sites
  • GSK Investigational Site
    Brugge, 8000, Belgium
  • GSK Investigational Site
    Brussel, 1090, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Aalborg, 9000, Denmark
  • GSK Investigational Site
    Odense, 5000 Odense C, Denmark
  • GSK Investigational Site
    Essey les Nancy, 54270, France
  • GSK Investigational Site
    Grasse, 06130, France
  • GSK Investigational Site
    Laon, 02000, France
  • GSK Investigational Site
    Nimes, 30900, France
  • GSK Investigational Site
    Oyonnax, 01100, France
  • GSK Investigational Site
    Paris cedex 15, 75730, France
  • GSK Investigational Site
    Paris, 75019, France
  • GSK Investigational Site
    Rouen Cedex, 76031, France
  • GSK Investigational Site
    Rouen, 76000, France
  • GSK Investigational Site
    Saint Michel, 16470, France
  • GSK Investigational Site
    Tours Cedex 1, 37000, France
  • GSK Investigational Site
    Vaux En Velin, 69120, France
  • GSK Investigational Site
    Villejuif, 94800, France
  • GSK Investigational Site
    Napoli, Campania 80138, Italy
  • GSK Investigational Site
    Foggia, Puglia 71100, Italy
  • GSK Investigational Site
    Palermo, Sicilia 90127, Italy
  • GSK Investigational Site
    Perugia, Umbria 06122, Italy
  • GSK Investigational Site
    Daugavpils, LV5403, Latvia
  • GSK Investigational Site
    Riga, LV 1004, Latvia
  • GSK Investigational Site
    Riga, LV 1064, Latvia
  • GSK Investigational Site
    Kaunas, LT-50425, Lithuania
  • GSK Investigational Site
    Taurage, LT-72214, Lithuania
  • GSK Investigational Site
    Vilnius, LT-10207, Lithuania
  • GSK Investigational Site
    Almere, 1315 RA, Netherlands
  • GSK Investigational Site
    Beek En Donk, 5741 CG, Netherlands
  • GSK Investigational Site
    Den Haag, 2517 EW, Netherlands
  • GSK Investigational Site
    Deurne, 5751 XJ, Netherlands
  • GSK Investigational Site
    Emmen, 7824 AA, Netherlands
  • GSK Investigational Site
    Ermelo, 3851 EX, Netherlands
  • GSK Investigational Site
    Nieuwegein, 3435 CM, Netherlands
  • GSK Investigational Site
    Spijkenisse, 3207 NB, Netherlands
  • GSK Investigational Site
    Tiel, 4002 WP, Netherlands
  • GSK Investigational Site
    Woerden, 3447 GN, Netherlands
  • GSK Investigational Site
    Drammen, N-3018, Norway
  • GSK Investigational Site
    Kongsvinger, N-2226, Norway
  • GSK Investigational Site
    Oslo, N-0855, Norway
  • GSK Investigational Site
    Bialystok, 15-274, Poland
  • GSK Investigational Site
    Krakow, 31-159, Poland
  • GSK Investigational Site
    Lodz, 93-513, Poland
  • GSK Investigational Site
    Lublin, 20-093, Poland
  • GSK Investigational Site
    Krasnoyarsk, 660022, Russian Federation
  • GSK Investigational Site
    Moscow, 115446, Russian Federation
  • GSK Investigational Site
    Moscow, 119435, Russian Federation
  • GSK Investigational Site
    Moscow, 119991, Russian Federation
  • GSK Investigational Site
    Novokuznetsk, 654063, Russian Federation
  • GSK Investigational Site
    Novosibirsk, 630099, Russian Federation
  • GSK Investigational Site
    St'Petersburg, 191144, Russian Federation
  • GSK Investigational Site
    Syktyvkar, 167011, Russian Federation
  • GSK Investigational Site
    Tomsk, 634 050, Russian Federation
  • GSK Investigational Site
    Almeria, 04009, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Madrid, 28006, Spain
  • GSK Investigational Site
    Madrid, 28009, Spain
  • GSK Investigational Site
    San Sebastián, 20014, Spain
  • GSK Investigational Site
    Sevilla, 41071, Spain
  • GSK Investigational Site
    Sollentuna, SE-191 24, Sweden
  • GSK Investigational Site
    Stockholm, SE-141 86, Sweden
  • GSK Investigational Site
    Stockholm, SE-171 76, Sweden
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2005 to primary completion in Oct 2006, 11 months.

Results were first posted in Apr 2017, 10 years 5 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 11 months is below that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2006
First posted
Jul 19, 2006
StartActual
Nov 18, 2005
Primary completionActual
Oct 26, 2006
CompletionActual
Oct 26, 2006
Results first posted
Apr 24, 2017
Last update
May 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00353873
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 19, 2006
Start date
Nov 18, 2005
Primary completion
Oct 26, 2006
Completion
Oct 26, 2006
Results posted
Apr 24, 2017
Last update
May 29, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate

Start the discussion